Barker, Fingert, Hayes-Jordan and Vadaparampil named to NCAB

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Anna D. Barker
Howard Fingert
Howard Fingert
Andrea Hayes-Jordan
Susan T. Vadaparampil

The White House has named the following individuals to the National Cancer Advisory Board:

  • Anna D. Barker, director of Arizona State University Transformative Healthcare Networks, co-director of the Complex Adaptive Systems Initiative and as a professor of practice within the School of Life Sciences. She is also a former NCI deputy director.

  • Howard Fingert, a long-time biotechnology company executive who now works as an industry consultant. Fingert is a member of the NCI Clinical Trials and Translational Research Advisory Committee and a former industry representative on the FDA Oncologic Drugs Advisory Committee.

  • Andrea Hayes-Jordan, chief of the Division of Pediatric Surgery at the UNC School of Medicine, and surgeon-in-chief at the North Carolina Children’s Hospital.

  • Susan T. Vadaparampil, associate center director of Community Outreach, Engagement, & Equity at Moffitt Cancer Center. She joined the Moffitt faculty after completing postdoctoral training at the NCI. Her work is focused on health disparities.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login